New hope for rare bone cancer: targeted drug AG-120 tested in small trial

NCT ID NCT04278781

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug AG-120 can safely slow or stop the growth of a rare bone cancer called chondrosarcoma that has a specific IDH1 gene mutation. Six adults with advanced or recurrent grade 2 or 3 chondrosarcoma will receive the drug. The main goal is to see how long the cancer stays under control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHONDROSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chondrosarcoma follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHONDROSARCOMA CHONDROSARCOMA, GRADE 2 CHONDROSARCOMA, GRADE 3 IDH1 GENE MUTATION

Contacts and locations

Locations

Columbia University (Specimen Analysis Only)

New York, New York, 10032, United States
Johns Hopkins Hospital (Data Collection Only)

Baltimore, Maryland, 21287, United States
MD Anderson Cancer Center (Data Collection Only)

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
The Ohio State University (Data Collection Only)

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.